Search
Molnupiravir
go.drugbank.com/drugs/DB15661InvestigationalMolnupiravir (EIDD-2801, MK-4482) is the isopropylester prodrug of N4-hydroxycytidine. With improved oral bioavailability in non-human primates, it is hydrolyzed in vivo, and distributes into tissues where it becomes the active 5’-tripho...
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseErythroxylum catuaba bark
go.drugbank.com/drugs/DB14300Investigational"Catuaba" is a general term for a medicinal infusion created by the bark of plants belonging to the _Erythroxylum_ genus, though this name is also applied to infusions of plants belonging to other genera … [A215262] The infusion is thought to carry stimulant and aphrodisiac effects,[A215262] and catuaba made specifically with _Trichilia catigua_ has been investigated for use in depression.[A215267]
Efprezimod alfa
go.drugbank.com/drugs/DB16448InvestigationalCD24Fc is a biological immunomodulator originally developed to address graft-versus-host disease in stem cell transplantation in leukemia patients.
Categories: Experimental Unapproved Treatments for COVID-19Sarconeos
go.drugbank.com/drugs/DB16457InvestigationalSarconeos is an activator of the MAS receptor.
Categories: Experimental Unapproved Treatments for COVID-19Empasiprubart
go.drugbank.com/drugs/DB16469InvestigationalEmpasiprubart is a humanized sweeping antibody designed to bind to C2, a protein in the complement cascade that leads to cell destruction when activated.
Categories: Experimental Unapproved Treatments for COVID-19STC3141
go.drugbank.com/drugs/DB16475InvestigationalSTC3141, was investigated in clinical trial NCT04880694 to evaluate its safety and effect in subjects with severe COVID-19 pneumonia.
Categories: Experimental Unapproved Treatments for COVID-19STI-1499
go.drugbank.com/drugs/DB16487InvestigationalSTI-1499 (COVI-GUARD was under investigation in clinical trial NCT04454398 to evaluate its safety and efficacy in patients with moderate COVID-19.
Categories: Experimental Unapproved Treatments for COVID-19TY027
go.drugbank.com/drugs/DB16500InvestigationalCategories: Experimental Unapproved Treatments for COVID-19BCc1
go.drugbank.com/drugs/DB16504ExperimentalBCc1 is a nanomedicine that demonstrated potent anticancer effects in both in vitro and in vivo studies.
Categories: Experimental Unapproved Treatments for COVID-19INS 316
go.drugbank.com/drugs/DB05390ExperimentalINS316 belongs to the family of drugs called nucleoside triphosphates.It is studied in the diagnosis of lung diseases, including lung cancer. It is selective P2y2 receptor antagonists claimed to be useful as anti-inflammatory agents.